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Purpose: The objective of this study is to assess the safety and efﬁcacy of switching to brinzolamide 1%
and timolol 0.5% ﬁxed combination (BTFC) from prior pharmacotherapy in patients with open-angle
glaucoma (OAG) or ocular hypertension (OH) in Taiwan.
Methods: This was a multicenter, open-labeled, interventional prospective study. The 8-week study
involved patients with OAG or OH with uncontrolled intraocular pressure (IOP) and consisted of three
study visits to the clinical site. Patients were instructed to discontinue their prior medications at the ﬁrst
visit, prior to starting the study medication. Enrolled patients were dosed with BTFC twice daily in both
eyes for 8 weeks. IOP measurements and safety evaluations were conducted at both Week 4 and Week 8.
Results: A total of 74 patients were enrolled. The overall mean IOP reductions from baseline after Week 8
of BTFC was 3.45 mmHg (15.42%); when subgrouped by prior medication class (b-blockers vs. non-b-
blockers), the reduction in mean IOP after transitioning to BTFC at Week 8 was as follows: subgroup
b-blockers were 3.23 mmHg (14.9 %) and non-b-blockers were 3.58 mmHg (15.25%). All mean IOP
changes from baseline were statistically signiﬁcant (p < 0.001). Of the 69 patients (per protocol pop-
ulation) who were switched to BTFC regardless of prior therapy, 37 (53.6%) patients at Week 4 and 38
(55.1%) patients at Week 8 had IOP  18 mmHg. No treatment-related serious adverse events were re-
ported in this study.
Conclusion: The results of this study demonstrated the potential beneﬁt of using BTFC as a replacement
therapy in order to ensure adequate IOP control. BTFC administered twice daily was safe and effective in
patients with uncontrolled IOP in Taiwan.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Glaucoma is a progressive optic neuropathy characterized by
degeneration of retinal ganglion cells, cupping of the optic nerve
heads, and visual ﬁeld defects often related to elevated intraocular
pressure (IOP). The disease affects 70million peopleworldwide and
is the second most common cause of blindness. It is estimated that
by the year 2020, this number will rise to around 79.6 million.1logy, Taipei Veterans General
ict, Taipei City 11217, Taiwan,
L. Liu).
e Ophthalmologic Society of TaiwTopical IOP-lowering medications remain the primary treat-
ment option for a majority of glaucoma patients. In many glaucoma
patients, treatment with a single therapeutic agent (monotherapy)
is often ineffective in providing long-term control of IOP, and these
patients eventually require the addition of another IOP-lowering
medication adjunctive to their current regimen to achieve
adequate IOP control. A signiﬁcant number of patients with ocular
hypertension (OH) or open-angle glaucoma (OAG) will require
more than one medication to achieve adequate control of IOP.
Nearly 40% of patients in the Ocular Hypertension Treatment Study
required two or more medications to achieve a 20% reduction in
IOP.2 Adjunctive therapy involving multiple medication bottles
adds complexity to the treatment regimen when compared withan. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics of patients.
Demographics Number (%)
Safety population 74 (100)
Gender
Male 32 (43.2)
Female 42 (56.8)
Diagnosis
OAG 59 (80)
Ocular hypertension 15 (20)
ITT population 73 (98.6)
PP population 69 (93.5)
Discontinued from the study 5 (6.76)
Reasons for discontinuation
Uncontrolled IOP 0 (0.0)
Personal reasons 1 (20.00)
Poor compliance 1 (20.00)
Adverse events 3 (60.00)
Lost to follow-up 0 (0.0)
IOP ¼ intraocular pressure; ITT ¼ intent to treatment; OAG ¼ open-angle
glaucoma; PP ¼ per protocol.
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coadministered drops are not spaced adequately in time.3 The
requirement of more than one therapy to control IOP is inconve-
nient to the patient and often leads to noncompliance. Fixed
combinations (FCs) of commonly coadministered IOP-lowering
agents have been developed to minimize these issues, offering
simpliﬁcation of the dosing regimen and elimination of the
washout effect.4,5
Topical carbonicanhydraseinhibitors (e.g.,AZOPTdbrinzolamide
1%) and beta-adrenergic blocking agents (e.g., timolol 0.5%) have been
used adjunctively to treat elevated IOP in patients with glaucoma and
OH, who cannot achieve target IOP on a single therapeutic regimen.
Clearly, the ability to combine twomedications in a single formulation
should enhance patient compliance, while maintaining better IOP
control than a single therapeutic regimen.6
Brinzolamide 1% and timolol 0.5% ﬁxed combination (BTFC)
(AZARGA, Alcon Laboratories, Inc., Fort Worth, TX, USA) was
approved for the reduction of elevated IOP in patients with OAG or
OH for whom monotherapy provides insufﬁcient IOP reduction.
Although several clinical studies have been conducted to assess the
safety and efﬁcacy of BTFC, more studies are needed to determine
its IOP-lowering effect in patients who cannot achieve target IOP
while on a single or multiple therapeutic regimen.6 The objective of
this open-label, 8-week study was to assess the safety and efﬁcacy
of switching to BTFC from prior pharmacotherapy in patients with
OAG or OH in Taiwan.
2. Methods
2.1. Patients
This was an open-label, 8-week, multicenter study in patients
with OAG or OH. Patients were recruited from the outpatient clinic
in the Department of Ophthalmology at the Veterans General
Hospital (Taipei, Taichung, and Kaoshiung), Taiwan, from July 2011
to March 2012. Eligible patients were 20 years of age or older with
bilateral OAG or OH. Eligible patients had to have a baseline IOP of
between 19 and 35 mmHg while being on either a single thera-
peutic agent or two separate ocular hypotensive agents, and they
required a change from their current hypotensive medications to
BTFC to achieve target IOP. They required to have a best-corrected
visual acuity of 6/60 (1.0 LogMAR) or better in each eye. Patients
were excluded from this study if they had any of following condi-
tions: a closed or barely open anterior chamber angle; a history of
ocular surgery or ocular inﬂammation within the past 3 months;
any history of ocular ﬁltering surgery, severe trauma, or argon laser
trabeculoplasty; current use of contact lenses or oral ocular hypo-
tensive agents; known hypersensitivity to any components of the
study medications; participation in another clinical study within 1
month prior to the screening visit; progressive retinal or optic
nerve disease from any cause; a history of, or at risk for, uveitis or
cystoid macular edema; a history of ocular herpes simplex; use of
systemic medications known to affect IOP, which have not been on
a stable course for 7 days prior to screening visit/baseline visit, or
an anticipated change in the dosage during the course of the study;
bronchial asthma or a history of bronchial asthma, bronchial hyper-
reactivity, or severe chronic obstructive pulmonary disease that
would preclude the safe administration of a topical beta-blocker;
a history of (or current) severe, unstable, or uncontrolled cardio-
vascular, hepatic, or renal disease that would preclude the safe
administration of a topical beta-blocker; hyperchloremic acidosis;
any clinically signiﬁcant, serious, or severe medical or psychiatric
condition; womenwhowere pregnant or lactating; participation in
any other investigational study within 30 days prior to the
screening visit; best-corrected visual acuity worse than 6/60 ineither eye; and any abnormality preventing reliable applanation
tonometry in either eye. Approval from the appropriate regulatory
authorities and ethics committees was obtained for each center,
and all patients provided signed informed consent prior to study
entry. The investigation was conducted according to the guidelines
of the Declaration of Helsinki.
2.2. Protocol
Evaluations included medical and ocular history, best-corrected
Snellen visual acuity, refraction, slit-lamp examination, ophthal-
moscopy through dilated pupils, visual ﬁeld testing with an auto-
mated perimetry threshold program, and IOP measurement by
Goldmann applanation tonometry. Previously treated patients
were instructed to discontinue their prior medications, without
a washout period at baseline prior to the switch period. All patients
were given one drop of BTFC twice daily in both eyes. Follow-up
visits were conducted after 4 and 8 weeks of treatment. We took
bilateral IOPmeasurements for each patient at the same time of the
scheduled visits to avoid diurnal variations. Study procedures that
were repeated at each follow-up visit included review of symp-
tomatology, and direct observation and collection of reports of
adverse events (AEs). AEs were summarized by system organ class
(SOC), preferred term, severity, and relationship to the study
medication using number and percentage. Any AE that occurred
during the study was rated and recorded.
2.3. Statistical analysis
Efﬁcacy was evaluated by calculating the mean IOP change from
baseline to each follow-up visit. Only patients with no missing IOP
measurements for all three visits were eligible for efﬁcacy evalua-
tion. Analyses were performed for both intent-to-treat (ITT) and
per protocol (PP) data sets, with the PP data set providing the
primary inference. SAS for Windows version 6.12 (SAS Institute,
Inc., Cary, NC, USA) was used for the efﬁcacy evaluation.
3. Results
3.1. Patient demography
This study was conducted from July 2011 to March 2012. Of the
74 enrolled patients, 69 were included in the PP analysis. Table 1
presents the number of safety population, ITT patients, and
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eligible for PP analysis. The median age of these patients was 60
years and 43% were male. Enrolled patients were diagnosed with
either primary OAG (80%) or OH (20%). Of the ﬁve discontinued
patients, three were discontinued from the study due to AEs
(Table 1).
3.2. Evaluation of efﬁcacy
The mean IOP at baseline for these patients was 22.0 
2.58 mmHg. Following a switch to BTFC, patients had a mean IOP of
18.54 2.86mmHg atWeek 4 and 18.55 3.08mmHg atWeek 8da
mean IOP decrease of 3.46mmHg (15.29%) and 3.45mmHg (15.42%)
from baseline (p < 0.0001) at Week 4 andWeek 8 visit, respectively
(Table 2). Among the patientswhowere switched to BTFC regardless
of prior therapy, 37 (53.6%) at Week 4 and 38 (55.1%) at Week 8 had
IOP 18 mmHg.
3.3. Prior beta-blocker therapy
The mean IOP in this group was reduced from
21.77  2.07 mmHg at baseline to 18.38  2.70 mmHg at Week 4
and 18.54  2.98 mmHg at Week 8. The mean change in IOP
was 3.38 mmHg (15.49%) at Week 4 and 3.23 mmHg
(14.90%) at Week 8. The observed mean change was statistically
signiﬁcant at both the visits (p < 0.0001). Among the patients who
were switched from a beta-blocker to the BTFC, 15 (57.7%) patients
at Week 4 and 15 (57.7%) patients at Week 8 had IOP 18 mmHg.
3.4. Prior non-beta-blocker therapy
For patients who switched from anymedication class other than
beta-blockers to BTFC, the mean IOP was reduced from
22.14  2.87 mmHg at baseline to 18.63  2.98 mmHg at Week 4
and 18.56  3.17 mmHg at Week 8. The mean change in IOP
was3.51 mmHg (15.16%) atWeek 4 and3.58mmHg (15.25%)
at Week 8. The observed mean change was statistically signiﬁcant
at both the visits (p < 0.0001). The non-beta-blocker group
included patients on a prior treatment regimen that included
brinzolamide 1% (N¼ 7), dorzolamide 2% (N¼ 8), FC of dorzolamide
2%/timolol 0.5% (N ¼ 1), prostaglandin analogs (bimatoprost 0.03%,
latanoprost 0.005%, or travoprost 0.004%) (N ¼ 11), FC of prosta-
glandin analogues (PGA)/timolol 0.5% (N ¼ 3), FC of brimonidine
0.2%/timolol 0.5% (N ¼ 2), brinzolamide 1% þ timolol 0.5% (N ¼ 4),Table 2
Efﬁcacy of brinzolamide/timolol ﬁxed combination treatmentdper protocol and subgrou
Per protocol population (N ¼ 69)
Mean IOP  SD (mmHg)
Mean IOP Change (%)
p
Number and percentage of patients having IOP <18 mmHg, N (%)
Subgroup of prior medication
b-Blockers (N ¼ 26)
Mean IOP  SD (mmHg)
Mean IOP Change (%)
p
Number and percentage of patients having IOP <18mmHg, N (%)
Any class (non-b-blockers) (N ¼ 43)
Mean IOP  SD (mmHg)
Mean IOP Change (%)
p
Number and percentage of patients having IOP <18 mmHg, N (%)
IOP ¼ intraocular pressure; SD ¼ standard deviation.dorzolamide 2% þ timolol 0.5% (N ¼ 4), or PGA þ timolol 0.5%
(N ¼ 3).
3.5. Safety evaluation
All 74 enrolled patients were evaluable for safety (Table 3).
There were total 18 (24.32%) patients who reported AEs. Majority of
the AEs belonged to the SOC “eye disorders” (n¼ 11; 14.86%). All the
AEs were considered as either mild or moderate in intensity. A total
of 13 (72.22%) patients experience at least one of the following AEs
that were deemed related to the study drug: palpitations, dry eye,
eye discharge, foreign body sensation in eyes, ocular hyperemia,
blurred vision, and nausea. Three patients were discontinued from
the treatment due to dry eye, blurred vision, or foreign body
sensation in eyes. There were no deaths or serious AEs in the study.
4. Discussion
This open-label, multicenter, interventional study was aimed at
assessing the safety and efﬁcacy of switching to AZARGA (BTFC), as
a replacement therapy in patients with uncontrolled IOP in Taiwan.
Of the total 74 patients enrolled in the study, 69 completed the
study. Of the ﬁve discontinued patients, three were discontinued
from the study due to AEs related to the study drug. Overall, the
study drug was well tolerated. The most common AE was blurred
vision. All the AEs were mild to moderate in intensity. Fifteen
patients had mild and three had moderate AEs. All the three
patients who had moderate AEs belonged to the SOC "eye disor-
ders"; 2twopatients had moderately blurred vision and one had
foreign body sensation in eyes, moderate in intensity. No serious
AEs or deaths were reported in the study. The most commonly
reported AEs belonged to the SOC "eye disorders" (n ¼ 11; 14.86%).
In Manni’s study,7,8 the most common adverse ocular effects of
the BTFC and FC of dorzolamide/timolol were blurred vision, eye
pain, and irritation. Blurred vision occurred more commonly in the
brinzolamide/timolol group than in the dorzolamide/timolol group
(3.6% vs. 0.5%), which was thought to be due to the suspension
formulation. Ocular pain (6.5% compared with 2.7%) and irritation
(10.6% compared with 2.7%) occurred more commonly in the dor-
zolamide/timolol group than in the brinzolamide/timolol group.
Other ocular reactions included foreign body sensation and
hyperemia. Overall, the dorzolamide/timolol group had a signiﬁ-
cantly greater number of reported side effects (23% vs. 14.1%),8,9
demonstrating that the BTFC might be better tolerated.p analysis.
Baseline Week 4 Week 8
22.00  2.58 18.54  2.86 18.55  3.08
3.46 (15.29%) 3.45 (15.42%)
<0.0001 <0.0001
37 (53.6) 38 (55.1)
21.77  2.07 18.38  2.70 18.54  2.98
3.38 (15.49%) 3.23 (14.9%)
<0.0001 <0.0001
15 (57.7) 15 (57.7)
22.14  2.87 18.63  2.98 18.56  3.17
3.51 (15.16%) 3.58 (15.25%)
<0.0001 <0.0001
22 (51.2) 23 (53.5)
Table 3
Ocular and systemic adverse eventsdsafety population (N ¼ 74).
No (%)
Number of patients with Adverse Events 18 (24.32)
Mild 15 (83.33)
Moderate 3 (16.67)
Serious 0 (0)
Ocular adverse event 11 (14.86)
Dry eye 1 (1.35)
Eye discharge 1 (1.35)
Foreign body sensation in eyes 2 (2.70)
Ocular hyperemia 9 (12.2)
Vision blurred 5 (6.76)
Systemic adverse event 9 (12.16)
Palpitations 1 (1.35)
Nausea 1 (1.35)
Abdominal pain upper 1 (1.35)
Insomnia 3 (4.05)
Pruritus 3 (4.05)
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monotherapy to study drug, a signiﬁcant reduction in mean IOP
was observed at subsequent visits from baseline; the mean change
in IOP was 3.38 mmHg at Week 4 and 3.23 mmHg at Week 8
(p ¼ 0.0002 at Week 4 and p ¼ 0.0009 at Week 8). When switched
to BTFC, more than half of the enrolled patients had an IOP
18 mmHg at the subsequent study visits (53.6%, 37/69 at Week 4;
55.1%, 38/69 at Week 8). The subgroup analysis did not show any
relevant difference in the mean change in IOP between two
subgroups (patients switched to BTFC from either beta-blockers or
non-beta-blockers) at Weeks 4 and 8. Similarly, no discernible
difference was observed in the percentage of patients having IOP
18 mmHg at the subsequent study visits between the two
subgroups: 51.2%, 22/43 at Week 4; 53.5%, 23/43 at Week 8 in the
non-beta-blocker group and 57.7%, 15/26 at Week 4; 57.7%, 15/26 at
Week 8 in beta-blocker group. The non-beta-blocker group
included patients on a prior treatment regimen that included an a-
2 agonist, a carbonic anhydrase inhibitor, a prostaglandin analog, or
other combinations (ﬁxed or unﬁxed). Due to the small sample size
of this subgroup, these non-beta-blocker classes were not analyzed
individually.
Various studies have evaluated the efﬁcacy of the BTFC therapy.7
In a double-masked, randomized, parallel-group, multicenter study
with a 6-month follow-up, a BTFC was compared with either
brinzolamide 1% or timolol 0.5%. The BTFC reduced IOP by
approximately 8.0 mmHg from baseline (29.6%). For timolol 0.5%
(dosed twice daily) and brinzolamide 1% (dosed twice daily), the
IOP reduction from baseline ranged from 5.7 to 6.9 mmHg (22.8e
26.1%) and from 5.1 to 5.6 mmHg (18.9e20.8%), respectively. The
BTFCwasmost effective at lowering IOP at all visits and time points.
These results showed that the FC was superior in IOP-lowering
efﬁcacy compared with each of its individual components.10Results of our study were similar to those of the previously pub-
lished BTFC study, assessing efﬁcacy where patients switched from
a prior therapy.11
Limitations of this study include the following: lack of a control
group due to its open-label design, small sample size for the
subgroup analysis, lack of monitoring of the patient’s compliance
prior to enrolling in the study and during the course of the study;
only one time point of the IOP measurement taken at baseline,
Week 4, and Week 8 visits; and lack of a washout period prior to
study initiation that could introduce bias due to potential side
effects of previous glaucoma medications.
To conclude, the results of this study showed that BTFC may be
a safe and efﬁcacious treatment alternative when Taiwanese
patients with either OAG or OH are unable to achieve target IOP
while on their current pharmacotherapy. The results were
comparable to those of the previously conducted studies.Acknowledgments
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